{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-455669","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2026-11-10T21:55:25+00:00","discovered_at":"2026-11-10T21:57:00.315622+00:00","generated_at":"2026-11-10T21:57:06.168215+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Acrivon introduces ACR-525 and PKCθ inhibitor preclinical I&I programs targeting EoE","bullets":["Nov 10, 2026 R&D webcast introduced ACR-525 and a PKCθ inhibitor, both preclinical, with initial development plans in eosinophilic esophagitis (EoE).","Dr. Arjan Bredenoord (Amsterdam UMC), EoE principal investigator, covered epidemiology and unmet need; Dr. Evan Dellon (UNC) reviewed EoE standard of care.","Programs were identified with Acrivon's AI-driven AP3 platform and mark the company's entry into immunology and inflammation.","No preclinical data, IND timing, trial endpoints or financial terms were disclosed; the posted exhibit is only a title slide."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-455669","json":"https://secwatch.observer/filing/0001193125-26-455669.json","markdown":"https://secwatch.observer/filing/0001193125-26-455669.md","text":"https://secwatch.observer/filing/0001193125-26-455669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526455669/0001193125-26-455669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526455669/acrv-20261110.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T21:57:06.168215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}